Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.4% in July

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a significant decline in short interest in July. As of July 31st, there was short interest totalling 884,100 shares, a decline of 20.4% from the July 15th total of 1,110,000 shares. Based on an average trading volume of 563,800 shares, the short-interest ratio is presently 1.6 days. Approximately 5.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On Vigil Neuroscience

Several hedge funds and other institutional investors have recently modified their holdings of the company. Strs Ohio bought a new stake in shares of Vigil Neuroscience in the fourth quarter worth about $27,000. Vanguard Group Inc. grew its position in shares of Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after buying an additional 95,276 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Vigil Neuroscience during the second quarter valued at approximately $26,000. Renaissance Technologies LLC raised its holdings in shares of Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after acquiring an additional 11,536 shares in the last quarter. Finally, Ensign Peak Advisors Inc lifted its stake in Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after acquiring an additional 166,442 shares during the period. 83.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on VIGL. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, July 11th. Guggenheim cut their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a report on Wednesday. Finally, JMP Securities reissued a “market outperform” rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Vigil Neuroscience Stock Performance

NASDAQ:VIGL traded up $0.54 during midday trading on Thursday, reaching $3.46. 270,334 shares of the stock traded hands, compared to its average volume of 289,912. The stock has a market capitalization of $130.04 million, a P/E ratio of -1.63 and a beta of 2.00. The company has a fifty day moving average of $4.02 and a 200 day moving average of $3.44. Vigil Neuroscience has a 12 month low of $2.47 and a 12 month high of $9.24.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.